| | | | | S-iii | | | |
| | | | | S-iii | | | |
| | | | | S-1 | | | |
| | | | | S-5 | | | |
| | | | | S-6 | | | |
| | | | | S-7 | | | |
| | | | | S-8 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-11 | | | |
| | | | | S-12 | | | |
| | | | | S-20 | | | |
| | | | | S-21 | | | |
| | | | | S-21 | | | |
| | | | | S-21 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 14 | | | |
| | | | | 16 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 24 | | | |
| | | | | 41 | | | |
| | | | | 52 | | | |
| | | | | 62 | | | |
| | | | | 66 | | | |
| | | | | 88 | | | |
| | | | | 90 | | | |
| | | | | 96 | | | |
| | | | | 97 | | | |
| | | | | 97 | | | |
| | | | | 97 | | |
£m
|
| |
Note
|
| |
2023
|
| ||||||
Share capital
|
| | | | | | | | | | 92 | | |
Other reserves
|
| | | | | | | | | | (10,960) | | |
Retained earnings
|
| | | | | | | | | | 27,474 | | |
Shareholders’ equity
|
| | | | | | | | | | 16,606 | | |
Non-controlling interests
|
| | | | | | | | | | 123 | | |
Total equity
|
| | | | | | | | | | 16,729 | | |
Short-term borrowings | | | | | | | | | | | | | |
Lease Liabilities
|
| | | | | | | | | | 48 | | |
Loan and overdrafts
|
| | | | | | | | | | 60 | | |
$700,000,000 3.024 per cent. callable notes due 2024
|
| | | | | | | | | | 548 | | |
Total short-term borrowings
|
| | | | 1 | | | | |
|
656
|
| |
Long-term borrowings | | | | | | | | | | | | | |
Lease Liabilities
|
| | | | | | | | | | 89 | | |
£300,000,000 2.875 per cent. notes due 2028
|
| | | | | | | | | | 299 | | |
£400,000,000 3.375 per cent. notes due 2038
|
| | | | | | | | | | 398 | | |
€850,000,000 1.250 per cent. notes due 2026
|
| | | | | | | | | | 707 | | |
€750,000,000 1.750 per cent. notes due 2030
|
| | | | | | | | | | 650 | | |
€750,000,000 2.125 per cent. notes due 2034
|
| | | | | | | | | | 646 | | |
$1,750,000,000 3.125 per cent. notes due 2025
|
| | | | | | | | | | 1,336 | | |
$2,000,000,000 3.375 per cent. notes due 2027
|
| | | | | | | | | | 1,561 | | |
$1,000,000,000 3.375 per cent. notes due 2029
|
| | | | | | | | | | 775 | | |
$2,000,000,000 3.625 per cent. notes due 2032
|
| | | | | | | | | | 1,551 | | |
$1,000,000,000 4.000 per cent. notes due 2052
|
| | | | | | | | | | 763 | | |
Non-Voting Preference Shares
|
| | | | | | | | | | 25 | | |
Total long-term borrowings
|
| | | | 1 | | | | |
|
8,800
|
| |
Total borrowings
|
| | | | | | | | | | 9,456 | | |
Total capitalization
|
| | |
|
2
|
| | | | | 26,185 | | |
| | |
Ordinary Shares Beneficially Owned
Before the Completion of the Global Offer |
| |
Ordinary Shares
Being Sold by Securityholder in the Global Offer |
| |
Ordinary
Shares Being Sold by Securityholder in the Share Buyback |
| |
Ordinary Shares Beneficially
Owned After Completion of the Global Offer and the Share Buyback |
| ||||||||||||
Name and Address of
Selling Securityholder |
| |
Number of
Ordinary Shares(1)(2) |
| |
Percentage of
Outstanding Ordinary Shares(1)(2) |
| |
Number of
Ordinary Shares(1)(3)(4) |
| |
Number of
Ordinary Shares(1)(3) |
| |
Number of
Ordinary Shares(3)(4) |
| |
Percentage of
Outstanding Ordinary Shares(3)(4)(5) |
| ||||||
Pfizer Inc.
|
| | | | 2,955,063,626 | | | | | | 32.00% | | | | | | | | | | | | | | |
|
Record Date
|
| |
Payable Date
|
| |
Amount Per
Ordinary Share (pence) |
| |
Amount Per
ADS (dollars) |
| ||||||
|
March 17, 2023
|
| |
April 27, 2023
|
| | | | 2.4 | | | | | | 0.0597319 | | |
|
August 25, 2023
|
| |
October 5, 2023
|
| | | | 1.8 | | | | | | 0.043871 | | |
Underwriters
|
| |
Number of
Ordinary Shares |
| |
Number of
ADSs(1) |
| ||||||
Citigroup Global Markets Inc.
|
| | | | | | | | | | | | |
Citigroup Global Markets Limited
|
| | | | | | | | | | | | |
Morgan Stanley & Co. LLC
|
| | | | | | | | | | | | |
Barclays Bank PLC
|
| | | | | | | | | | | | |
Barclays Capital Inc.
|
| | | | | | | | | | | | |
J.P. Morgan Securities LLC
|
| | | | | | | | | | | | |
J.P.Morgan Securities plc
|
| | | | | | | | | | | | |
UBS AG, London Branch
|
| | | | | | | | | | | | |
UBS Securities LLC
|
| | | | | | | | | | | ||
Total
|
| | | | | | | | | | | | |
| | |
Per Ordinary
Share |
| |
Per ADS
|
| |
Total(1)
|
| |||||||||
Public offering price
|
| | | £ | | | | | $ | | | | | $ | | | |||
Underwriting discounts and commissions to be paid by the Selling Securityholder(2)
|
| | | £ | | | | | $ | | | | | $ | | | |||
Proceeds, before expenses, to the Selling Securityholder
|
| | | £ | | | | | $ | | | | | $ | | | |
| Section 96 (1) (a) | | | the offer, transfer, sale, renunciation or delivery is to: | |
| | | | (i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; | |
| | | | (ii) the South African Public Investment Corporation; | |
| | | | (iii) persons or entities regulated by the Reserve Bank of South Africa; | |
| | | | (iv) authorised financial service providers under South African law; | |
| | | | (v) financial institutions recognised as such under South African law; | |
| | | | (vi) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or | |
| | | | (vii) any combination of the person in (i) to (vi); or | |
| Section 96 (1) (b) | | | the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. | |
|
SEC registration fee
|
| | | $ | * | | |
|
FINRA fees
|
| | | | | | |
|
Printing expenses
|
| | | | | | |
|
Legal fees and expenses
|
| | | | | | |
|
Accountants’ fees and expenses
|
| | | | | | |
|
Miscellaneous
|
| | | | | | |
| Total | | | | | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 14 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 41 | | | |
| | | | 52 | | | |
| | | | 62 | | | |
| | | | 66 | | | |
| | | | 88 | | | |
| | | | 90 | | | |
| | | | 96 | | | |
| | | | 97 | | | |
| | | | 97 | | | |
| | | | 97 | | |
£m
|
| |
Note
|
| |
2022
|
| ||||||
Share capital
|
| | | | | | | | | | 92 | | |
Share premium
|
| | | | | | | | | | — | | |
Other reserves
|
| | | | | | | | | | (11,537) | | |
Translation reserve
|
| | | | | | | | | | 1,046 | | |
Retained earnings
|
| | | | | | | | | | 26,730 | | |
Shareholders’ equity
|
| | | | | | | | | | 16,331 | | |
Non-controlling interests
|
| | | | | | | | | | 126 | | |
Total equity
|
| | | | | | | | | | 16,457 | | |
Short-term borrowings | | | | | | | | | | | | | |
Lease Liabilities
|
| | | | | | | | | | 44 | | |
Loan and overdrafts
|
| | | | | | | | | | 91 | | |
Commercial paper
|
| | | | 1 | | | | | | 302 | | |
Total short-term borrowings
|
| | | | 4 | | | | |
|
437
|
| |
Long-term borrowings | | | | | | | | | | | | | |
Lease Liabilities
|
| | | | | | | | | | 117 | | |
£300,000,000 2.875 per cent. notes due 2028
|
| | | | 1 | | | | | | 299 | | |
£400,000,000 3.375 per cent. notes due 2038
|
| | | | 1 | | | | | | 398 | | |
€850,000,000 1.250 per cent. notes due 2026
|
| | | | 1 | | | | | | 694 | | |
€750,000,000 1.750 per cent. notes due 2030
|
| | | | 1 | | | | | | 663 | | |
€750,000,000 2.125 per cent. notes due 2034
|
| | | | 1 | | | | | | 659 | | |
$700,000,000 3.024 per cent. callable notes due 2024
|
| | | | 1 | | | | | | 581 | | |
$300,000,000 floating rate SOFR + 0.89 per cent. callable notes due 2024
|
| | | | 1,3 | | | | | | 249 | | |
$1,750,000,000 3.125 per cent. notes due 2025
|
| | | | 1 | | | | | | 1,385 | | |
$2,000,000,000 3.375 per cent. notes due 2027
|
| | | | 1 | | | | | | 1,653 | | |
$1,000,000,000 3.375 per cent. notes due 2029
|
| | | | 1 | | | | | | 822 | | |
$2,000,000,000 3.625 per cent. notes due 2032
|
| | | | 1 | | | | | | 1,652 | | |
$1,000,000,000 4.000 per cent. notes due 2052
|
| | | | 1 | | | | | | 806 | | |
Non-Voting Preference Shares
|
| | | | 1 | | | | | | 25 | | |
Total long-term borrowings
|
| | | | 4 | | | | |
|
10,003
|
| |
Total borrowings
|
| | | | | | | | | | 10,440 | | |
Total capitalization
|
| | |
|
2
|
| | | | | 26,897 | | |
| |
In the remainder of this description “you” means direct holders and not street name or other indirect holders of securities. Indirect holders should read the previous subsection entitled “Street Name and Other Indirect Holders.”
|
| |
Shareholder
|
| |
Class
|
| |
Number of shares
|
| |
Voting rights
|
| |||
Pfizer (including interests in Ordinary Shares held indirectly through holdings of ADSs)
|
| |
Ordinary Shares
|
| | | | 2,955,063,626 | | | |
32.00 per cent.
|
|
GSK and certain controlled undertakings of GSK
|
| |
Ordinary Shares
|
| | | | 955,320,110 | | | |
10.35 per cent.
|
|
Other holders of Ordinary Shares (including interests
in Ordinary Shares held indirectly through holdings of ADSs) |
| |
Ordinary Shares
|
| | | | 5,324,190,095 | | | |
57.65 per cent
|
|
| | You should consult your own tax advisor regarding the U.S. federal, state and local and other tax consequences of owning and disposing of offered securities in your particular circumstances. | | |
Name of Selling Securityholder
|
| |
Ordinary Shares
Beneficially Owned Prior to the Offering(1) |
| |
Number of
Ordinary Shares Being Offered(1) |
| |
Ordinary Shares
Beneficially Owned After the Ordinary Shares are Sold(2) |
| |||||||||||||||||||||
| | |
Number
|
| |
x%
|
| | | | | | | |
Number
|
| |
x%
|
| ||||||||||||
Pfizer Inc.(3)
|
| | | | 2,955,063,626 | | | | | | 32.00 | | | | | | 2,955,063,626 | | | | | | — | | | | | | — | | |
GSK and certain of its controlled undertakings(4)
|
| | | | 955,320,110 | | | | | | 10.35 | | | | | | 955,320,110 | | | | | | — | | | | | | — | | |
|
Securities and Exchange Commission registration fee
|
| | | $ | (1)(2)* | | |
|
Printing expenses
|
| | | | * | | |
|
Legal fees and expenses
|
| | | | * | | |
|
Accountants’ fees and expenses
|
| | | | * | | |
|
Trustee fees and expenses
|
| | | | * | | |
|
Miscellaneous
|
| | | | * | | |
| Total | | | |
|
*
|
| |
|
Citigroup
|
| | | | |
Morgan Stanley
|
|
|
Barclays
|
| |
J.P. Morgan
|
| |
UBS Investment Bank
|
|
6F/,Q[1@UK!%BJ;TNAJ:M
M58FE );#B&PDJ!(UR,$)1T8,_>8]Q]0._ '1@S]YCW'U [\ =/WF/4#O
MP!T8,_>8]Q]0._ '1@S]YCW'U [\ =/WF/4#OP#3[C.4>967F.\0W#&N
M&ZNS4#]N2PS45( 2MWE K9$CQ""GS@)+YL[NF==[S-Q7>+;@JX5-MJ[B\]35
M"$C9<;6?!4G3J,!XWHP9^\Q[CZ@00=/WF/4#OP!T8,_>8]Q]0._ '1@S
M]YCW'U [\ =/WF/4#OP!T8,_>8]Q]0._ -)N+Y09EY=Y@8CN>-<-U=FH
M*BUI89J*D)"5N\LE6R)$Z9"< ^T%$!\JAANI96P\A+C3@*7&W$A2%).@A0.@
M@P"BYU;B.#,9NU-_RZJ4X6Q ]-;M 4[=M><5,D[.MLDG@F(!*L=;L6=F 77/
MA;"E35T:#)-PM8-6PH?:35I[4$